Artelo Biosciences : Annual Transition Report (Form 10-KT)

artl_10kt.htm














UNITED STATES


SECURITIES AND EXCHANGE COMMISSION
... | March 21, 2022

Related Keywords

Japan ,Nevada ,United States ,United Kingdom ,Washington ,Solana Beach ,California ,China ,San Diego County ,Ireland ,Dublin ,Canada ,Spain ,America ,Canadian ,Japanese ,Lomas Santa Fe ,Trinity College Dublin ,Good Laboratory Practice ,Research Development ,Astrazeneca ,Pfizer Inc ,Clinical Health ,Tetra Bio Pharma Inc ,Department Of Justice ,Stony Brook University Relationship ,National Institutes Of Health ,University Of Western Ontario ,Drug Administration ,Children Health Insurance Program ,Trinity Reliant Ventures ,Artelo Biosciences Inc ,Biopharmaceuticals Inc ,Nasdaq Stock Market ,Securities Exchange ,International Laws ,Helsinn Therapeutics Us Inc ,Jazz Pharmaceuticals Inc ,Development Phase ,Us Health Insurance Portability ,Foundation The Patent Rights ,Nasdaqstock Market ,European Union ,Novartis International ,Administration Of Oral Single Ascending Doses ,Health Information Technology For Economic ,Growth Company ,Artelo Biosciences ,Stony Brook University ,European Medicines Agency ,Artelo Biosciences Corporation ,Mark One ,Zip Code ,Pact Yes ,Securities Exchange Act ,Interactive Data File ,Regulations T ,Sarbanes Oxley Act ,Exchange Act ,Common Stock ,Transition Report ,Financial Condition ,United States Dollars ,Trinity Reliant Ventures Limited ,Artelo Biosciences Limited ,Cancer Appetite Recovery Study ,Fatty Acid Binding Protein ,National Institutes ,Post Traumatic Stress Disorder ,Western Ontario ,Inflammatory Bowel Disease ,Candidate Pipeline ,Cannabinoid Agonist ,Bowel Disease ,Transition Reports ,Annual Reports ,Quarterly Reports ,Current Reports ,First Amendment ,Data Transfer ,License Agreement ,Single Ascending Dose ,Multiple Ascending Dose ,First Time ,Placebo Controlled Study ,Investigate Safety ,Oral Single Ascending Doses ,Healthy Volunteers ,Japanese Healthy Male Volunteers ,Placebo Controlled Crossover Study ,Evaluate Effects ,Single Oral Dose ,Topical Capsaicin Evoked Pain ,Double Blind ,Analgesic Efficacy ,Single Dose ,Interaction Study ,After Administration ,Oral Multiple Ascending Doses ,Adult Subjects ,Chronic Low Back ,Research Foundation ,Stony Brook Agreement ,Patent Product ,Annual Minimum Royalty ,Annual Minimum ,Licensed Subject Matter ,First Commercial Sale ,Net Sales ,Helsinn Therapeutics ,Tetra Bio Pharma ,Federal Food ,Cosmetic Act ,Laboratory Practice ,Investigational New Drug ,Good Manufacturing Practice ,Risk Evaluation ,Mitigation Strategy ,Foreign Corrupt Practices Act ,Anti Kickback Statute ,False Claims Act ,Insurance Portability ,Accountability Act ,Health Information Technology ,Clinical Health Act ,Payments Sunshine Act ,Health Insurance Program ,Nc Stock Exchange ,News ,Information ,Press Release ,United ,Securities ,End ,Xchange Artl Us04301g2012 ,